TICKERNERD
Menu
ACHACHHealthcare · Medical Distribution

ACH Stock Forecast: Accendra Health, Inc. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$0.87
−1.90% on the day

The 6 Wall Street analysts covering Accendra Health, Inc. hold a median 12-month price target of $1.5 — +71.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 21 Sept 2026 — in the lower half.

Market cap
$68.4M
Ticker Nerd rank
44 / 100
Median analyst target
$1.50
Analysts covering
6
Revenue$613.2M−10.1% y/y
Operating income$19.8M
Net income−$89.1M
Free cash flow−$74.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.0%
1M
−27.2%
YTD
−68.8%
1Y
−83.3%
From 52W high
−84.2%
From 52W low
0.0%
$0.87
$5.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Accendra Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Sept 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
96
Size
79
Quality
63
Accruals
59
Value
56
Growth
42
Revisions
27
Volatility
16
Momentum
5

Issuance (96): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26ACHHigh $1.75Median $1.50Low $1.30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
0 Buy4 Hold2 Sell
Low $1.30Median $1.50High $1.75

The green dot is the last close — the median target sits +71.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Aug 2026UBSMaintainsNeutral$4.50 → $1.50
11 Aug 2026CitigroupDowngradeNeutral$4.50 → $1.50
24 July 2026CitigroupMaintainsBuy—
24 July 2026CitigroupMaintainsBuy$5.00 → $4.50
12 May 2026BairdMaintainsOutperform$5.00 → $6.00
12 May 2026BairdMaintainsOutperform—
12 May 2026CitigroupMaintainsBuy$3.25 → $5.00
12 May 2026CitigroupMaintainsBuy—
12 May 2026UBSMaintainsNeutral—
12 May 2026UBSMaintainsNeutral$3.00 → $4.50
20 Feb 2026Leerink PartnersMaintainsMarket Perform—
9 Jan 2026CitigroupMaintainsBuy—
3 Nov 2025UBSDowngradeNeutral—
27 Aug 2025JP MorganMaintainsUnderweight—
13 Aug 2025UBSMaintainsBuy—
12 Aug 2025B of A SecuritiesMaintainsUnderperform—
12 Aug 2025BairdMaintainsOutperform—
12 Aug 2025CitigroupMaintainsBuy—
25 Aug 2022Goldman SachsUpgradeNeutral—
7 Jan 2020Goldman SachsDowngradeSell—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, Accendra Health, Inc. returned −83.3% against +17.8% for the S&P 500, dividends included.

ACH vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26ACHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−109.9%
Analysts raising
0
Analysts cutting
5
Fundamentals

Accendra Health, Inc. (ACH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.8×

Cheaper than 60% of US stocks

Price / sales
0.0×

Cheaper than 99% of US stocks

Price / book
−0.1×

Cheaper than 93% of US stocks

EV / EBITDA
6.5×

Cheaper than 50% of US stocks

Growth & margins
Revenue growth (YoY)
−10.1%

Higher than 16% of US stocks

Earnings growth (YoY)
−10.1%

Higher than 26% of US stocks

Gross margin
43.0%

Higher than 53% of US stocks

Operating margin
−1.5%

Higher than 31% of US stocks

Net margin
−11.4%

Higher than 19% of US stocks

Returns & dividend
Return on equity
238.8%

Higher than 99% of US stocks

Return on assets
0.6%

Higher than 47% of US stocks

Dividend yield
1.3%

Higher than 30% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Accendra Health, Inc. (ACH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Accendra Health, Inc. has a market value of $68.4M and an enterprise value of $1.9B.

  • Revenue in the twelve months to 30 June 2026: $2.6B. The latest quarter shrank 10.1% year on year.

  • Net income over the same four quarters: −$302.1M, a −11.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.91.

  • Free cash flow in the twelve months to 30 June 2026: −$365.6M.

  • Accendra Health, Inc. spent $3.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 76.9M.

  • Trailing P/E: 8.8×; forward P/E: 5.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.29%, paying out 0% of earnings.

  • Accendra Health, Inc. employs 6,500 people — $407K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Sept 2026

Data provided by Twelve Data

Peers

ACH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
ACHAccendra Health, Inc.$68.4M
44
COSMCosmos Health, Inc.$34.1M
18
MEDSDataMeds AI, Inc.$12.7M
14
RNTXRein Therapeutics, Inc.*$68.0M
37
KLRSKalaris Therapeutics, Inc.*$68.0M
20
XBITXBiotech, Inc.*$66.5M
31
HYFTMindWalk Holdings Corp.*$68.6M
49

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Accendra Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACH news & analysis

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth

Business Wire · 17 Sept 2026positive

Accendra Health named Kenneth Gardner-Smith as its next President and Chief Executive Officer, succeeding Edward A. Pesicka, who plans to retire. Gardner-Smith, a board member since March 2022, is expected to take the role early in the fourth quarter of 2026.

Why it matters — The appointment brings a new CEO with experience in large-scale patient care operations to lead Accendra Health through a leadership transition and its next phase of growth.

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

Business Wire · 17 Aug 2026neutral

Accendra Health announced it will not pursue an at-the-market equity issuance program, which had been intended to raise modest amounts of equity over time to reduce debt, and provided an update on the timeline for replacing its chief executive officer. The decision was made given recent market conditions and in the interest of stakeholders.

Why it matters — Accendra Health watchers would care because the company's capital allocation approach and CEO succession timing directly affect its financial strategy and leadership transition.

Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript

Seeking Alpha · 10 Aug 2026neutral

Accendra Health, Inc. held its Q2 2026 earnings call, with the transcript published by Seeking Alpha.

Why it matters — The earnings call transcript provides investors and analysts with management's discussion of the company's quarterly financial performance and outlook.

Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value

Business Wire · 10 Aug 2026positive

Accendra Health's Board of Directors adopted a Section 382 Rights Agreement, called the Tax Asset Preservation Plan, designed to protect long-term shareholder value by helping the company preserve its net operating loss carryforwards and other tax attributes. The plan addresses potential changes in stock ownership by certain 5-percent holders.

Why it matters — ACH watchers would care because preserving the company's net operating losses and tax attributes can protect shareholder value against ownership changes that might otherwise limit those benefits.

Accendra Health Reports Second Quarter 2026 Financial Results

Business Wire · 10 Aug 2026neutral

Accendra Health, Inc. (NYSE: ACH) reported its financial results for the second quarter ended June 30, 2026, reflecting the Company's continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. During the quarter, the Company made further progress toward the complete separation from Owens & Minor and addressed a large commercial payor exit.

Why it matters — An ACH watcher would care because the report signals continued progress on the separation from Owens & Minor, a structural change central to the Company's identity and future performance.

FAQ

Frequently asked questions about ACH stock

What is the ACH stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Accendra Health, Inc. have a median 12-month price target of $1.5, with estimates ranging from $1.3 to $1.75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACH stock a buy right now?

Of the 6 analysts covering Accendra Health, Inc., 0 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Accendra Health, Inc. 44 out of 100 across roughly 4,600 US stocks as at 21 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACH?

As at 21 Sept 2026, Accendra Health, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (96 of 100).

Will ACH stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +71.8% from the last close, and Ticker Nerd's factor model ranks Accendra Health, Inc. 44 out of 100 as at 21 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACH stock forecast for 2030?

No analyst covering Accendra Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.3 to $1.75 over the next 12 months.

How has ACH stock performed over the past year?

Accendra Health, Inc. returned -83.3% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Accendra Health, Inc. do?

Accendra Health Inc. is a healthcare solutions company focused on delivering products, technology, and services that support care beyond the hospital.

What is the latest news on ACH?

The most recent item we track (Business Wire, 17 Sept 2026): "Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth". Accendra Health named Kenneth Gardner-Smith as its next President and Chief Executive Officer, succeeding Edward A. Pesicka, who plans to retire. Gardner-Smith, a board member since March 2022, is expected to take the role early in the fourth quarter of 2026.

Company

About Accendra Health, Inc.

Accendra Health Inc. is a healthcare solutions company focused on delivering products, technology, and services that support care beyond the hospital. The company serves patients, providers, and insurers through its home-based care platform, with offerings that include diabetes management supplies, respiratory support, sleep health solutions, wound care, urology, and ostomy products. Its Patient Direct operations, anchored by the Apria and Byram Healthcare brands, connect individuals with home medical equipment, patient support services, and ongoing care for chronic, complex, and acute conditions. Accendra Health Inc. also plays a role in medical distribution and related healthcare services, helping streamline access to essential supplies and care delivery across the United States. Headquartered in Glen Allen, Virginia, Accendra Health Inc. is positioned as a specialist in home health and post-hospital care support.

CEO Mr. Edward A. Pesicka · 6,500 employees · United States · https://www.accendrahealth.com